-
-
Several important papers have been published in the last 2 months, none more important than the realization that breast cancer rates have dropped precipitously since the publication of the Women's Health Initiative (WHI) in 2002.
-
Breast cancers that are "triple-negative" (ie, ER, PR, HER2-negative) are considered high risk, yet there remains variability, with some demonstrating less malignant features than others.
-
Breast cancer statistics indicate a rapid decrease in prevalence immediately after the publicity surrounding the reports from the Women's Health Initiative.
-
In a family-based research cohort, men were followed for up to 40 years after the birth of their children, and those with only daughters had a 40% higher risk of prostate cancer compared with men with at least one son.
-
Trastuzumab has previously been demonstrated to be active against HER2 positive breast cancer when used in the metastatic setting.
-
Imatinib inhibits the BCR/ABL tyrosine kinase in CML, leading to improved responses over standard therapy. This report provides 5 year follow-up from the seminal IRIS study of upfront imatinib for chronic phase CML among the 553 patients randomized to 400 mg of imatinib.
-
The lead paper in the November issue of Obstetrics and Gynecology should stimulate lively discussion regarding the counseling of patients of advanced maternal age (AMA), and, if taken at face value, could impact the field of prenatal diagnosis, in general.
-
The resection of tumor nodules (or cytoreduction) before primary chemotherapy has been linked closely with survival in patients with advanced epithelial ovarian cancer. Chi and colleagues set out to evaluate the merits of cytoreduction completeness in a homogeneous cohort of ovarian cancer patients with bulky metastatic disease.
-
Kahlenborn and colleagues performed a meta-analysis of case-control studies published after 1979 that focused on the use of oral contraceptives and the risk of premenopausal breast cancer.